This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, G.-H. Search for Related Content PubMed PubMed Citation Articles by Lee, G.-H. Social Bookmarking                   What's this?

Review Article: Paradoxical Effects of Phenobarbital on Mouse Hepatocarcinogenesis

Pathology Research Unit, National Yakumo Hospital, Yakumo-cho, Hokkaido 049-3198, Japan, lee{at}host.or.jp

Phenobarbital was the first tumor promoter for rodent liver to be associated with the 2-stage or initiation-promotion concept of carcinogenesis. In rats and mice preinitiated with genotoxic carcinogens, phenobarbital administration increases the number of hepatocellular tumors by approximately 5-fold despite its nongenotoxicity. However, in mice phenobarbital occasionally exhibits strong inhibitory effects on hepatocarcinogenesis initiated with the potent carcinogen diethylnitrosamine. Both positive and negative effects of phenobarbital on hepatocytic proliferation and apoptosis, which are mechanistically involved in the promotion stage of hepatocarcinogenesis, have been described. These complex outcomes of phenobarbital treatment and their effects on hepatocarcinogenesis in mice raise serious issues regarding extrapolation of experimental data from laboratory animals to human risk assessment. Recent work suggests that the paradoxical actions of phenobarbital on hepatocarcinogenesis can be understood by consideration of qualitative diversity in initiated lesions and differential responses to promotion stimulus.

Key Words: Hepatocarcinogenesis • phenobarbital • promotion • inhibition • mouse

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				N. Bhattacharjee, S. Pathak, and A. R. Khuda-Bukhsh Amelioration of Carcinogen-Induced Toxicity in Mice by Administration of a Potentized Homeopathic Drug, Natrum Sulphuricum 200 Evid. Based Complement. Altern. Med., June 19, 2007; (2007) nem067v1. [Abstract] [Full Text] [PDF]

				W. Bursch, M. Chabicovsky, U. Wastl, B. Grasl-Kraupp, K. Bukowska, H. Taper, and R. Schulte-Hermann Apoptosis in Stages of Mouse Hepatocarcinogenesis: Failure to Counterbalance Cell Proliferation and to Account for Strain Differences in Tumor Susceptibility Toxicol. Sci., May 1, 2005; 85(1): 515 - 529. [Abstract] [Full Text] [PDF]

				A. Nishikawa, T. Imazawa, Y. Kuroiwa, Y. Kitamura, K. Kanki, Y. Ishii, T. Umemura, and M. Hirose Induction of Colon Tumors in C57BL/6J Mice Fed MeIQx, IQ, or PhIP Followed by Dextran Sulfate Sodium Treatment Toxicol. Sci., April 1, 2005; 84(2): 243 - 248. [Abstract] [Full Text] [PDF]

				M. Hayashi, T. Tamura, J. Kuroda, H. Ohnota, N. Shibata, M. Akahane, Y. Kashida, and K. Mitsumori Different Inhibitory Effects in the Early and Late Phase of Treatment with KAT-681, a Liver-Selective Thyromimetic, on Rat Hepatocarcinogenesis Induced by 2-Acetylaminofluorene and Partial Hepatectomy after Diethylnitrosamine Initiation Toxicol. Sci., March 1, 2005; 84(1): 22 - 28. [Abstract] [Full Text] [PDF]

				J. E. Trosko and B. L. Upham The emperor wears no clothes in the field of carcinogen risk assessment: ignored concepts in cancer risk assessment Mutagenesis, March 1, 2005; 20(2): 81 - 92. [Abstract] [Full Text] [PDF]

				J. E. TROSKO, C.-C. CHANG, B. L. UPHAM, and M.-H. TAI Ignored Hallmarks of Carcinogenesis: Stem Cells and Cell-Cell Communication Ann. N.Y. Acad. Sci., December 1, 2004; 1028(1): 192 - 201. [Abstract] [Full Text] [PDF]

				X. Yang, J. Tang, C. E. Rogler, and P. Stanley Reduced Hepatocyte Proliferation is the Basis of Retarded Liver Tumor Progression and Liver Regeneration in Mice Lacking N-Acetylglucosaminyltransferase III Cancer Res., November 15, 2003; 63(22): 7753 - 7759. [Abstract] [Full Text] [PDF]